Gloucester Pharmaceuticals, Inc. Reports Positive Interim Phase II Data On Romidepsin For Peripheral T-Cell Lymphoma At The 2006 American Society of Hematology Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, today announced interim data for romidepsin (formerly known as depsipeptide, FK228) as a treatment for peripheral T-cell lymphoma (PTCL) at the American Society of Hematology Annual Meeting held in Orlando, FL. The data presented are part of an interim analysis of a phase II study sponsored by the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) with Gloucester.

>>> Discuss This Story

Back to news